---
title: "How AI Will Help You Live to 150 (Not Science Fiction)"
description: "5 source-backed AI claims from How AI Will Help You Live to 150 (Not Science Fiction), with key statistics, context, and the original AI Adopters Club source."
url: "https://kbanc.com/claims-library/how-ai-will-help-you-live-to-150-not-science-fiction"
source: "https://aiadopters.club/p/the-longevity-moonshot"
date: "2025-03-21"
topics: ["strategy", "business", "tools"]
generated: "2026-08-31"
---

# How AI Will Help You Live to 150 (Not Science Fiction)

By Kamil Banc | March 21, 2025

## Claims

1. **AI Aging Clocks** (source summary): Deep Longevity's AI aging clocks measure biological age using blood markers, DNA methylation, and microbiome data.
2. **AI-Designed Drug Reaches Trials** (source summary): Insilico Medicine's AI designed Rentosertib, an IPF drug reaching human trials in 18 months.
3. **Insilico's Growing Drug Pipeline** (source summary): By 2025, Insilico Medicine had over 30 drug candidates with 10 cleared for human trials.
4. **AI Rejuvenates Elderly Mice** (source summary): GERO.AI achieved systemic rejuvenation in elderly mice using AI-predicted interventions targeting aging.
5. **Regulatory Hurdles for Anti-Aging** (Kamil's interpretation): Aging is not classified as a disease, creating regulatory hurdles for anti-aging treatment approval.

## Evidence

### Quote
> "The research community has shifted from treating individual diseases to targeting the root causes of aging itself." - Kamil Banc

### Key Statistics
- **$2.7 billion to $4.1 billion**: The longevity market is projected to grow from $2.7 billion in 2023 to $4.1 billion by 2030.
- **Exceeded $1 billion**: Venture funding in longevity research has surpassed $1 billion, with investors including Sam Altman, Jeff Bezos, and Peter Thiel.
- **18 months**: Insilico Medicine's AI identified both the drug target and designed the Rentosertib molecule in 18 months, versus the typical decade-long process.
- **30+ candidates, 10 in trials**: By 2025, Insilico Medicine had accumulated more than 30 AI-designed drug candidates, with 10 cleared for human trials.

## Context
The article draws on company announcements, peer-reviewed research, and market analyses to map AI's role in longevity science, citing sources from King's College London, PubMed, GERO.AI, and Deloitte. Practitioners can apply these insights by understanding how biological aging clocks, AI-driven drug discovery pipelines, and digital twin assessments shift healthcare from reactive treatment to prevention. For business leaders, the practical takeaway is anticipating disruption to insurance models, retirement planning, and workforce dynamics as longevity technologies mature. The author balances optimism with caution, flagging biological complexity, data quality, ethics, and regulation as unresolved obstacles before lifespan predictions like 150 years become reality.

## Source
- Original: [How AI Will Help You Live to 150 (Not Science Fiction)](https://aiadopters.club/p/the-longevity-moonshot)
- Cite: kbanc.com/claims-library/how-ai-will-help-you-live-to-150-not-science-fiction

## Primary Evidence
- [Deep Longevity](https://www.kcl.ac.uk/news/researchers-ai-ageing-clocks-predict-health-lifespan) (kcl.ac.uk; supports claim 1)
- [Insilico Medicine](https://www.news-medical.net/news/20250222/AI-driven-discovery-unveils-TNIK-inhibition-as-anti-aging-strategy.aspx) (news-medical.net; supports claims 2, 3)
- ["systemic rejuvenation"](https://gero.ai/validation) (gero.ai; supports claim 4)